Zobrazeno 1 - 10
of 99
pro vyhledávání: '"Jessica Ailani"'
Publikováno v:
Neurology and Therapy, Vol 13, Iss 6, Pp 1535-1540 (2024)
Externí odkaz:
https://doaj.org/article/57a0877348da4184b7ff7d0b17021a4c
Autor:
Nina Sharp, Mark J Burish, Kathleen B Digre, Jessica Ailani, Mahya Fani, Sophia Lamp, Todd J. Schwedt
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-12 (2024)
Abstract Background Patients with migraine often have poor sleep quality between and during migraine attacks. Furthermore, extensive research has identified photophobia as the most common and most bothersome symptom in individuals with migraine, seco
Externí odkaz:
https://doaj.org/article/30b7279e07824c7889324b26d8a0aa15
Autor:
Paul Rizzoli, Michael J. Marmura, Jennifer Robblee, Jennifer McVige, Sara Sacco, Stephanie J. Nahas, Jessica Ailani, Rosa De Abreu Ferreira, Julia Ma, Jonathan H. Smith, Brett Dabruzzo, Messoud Ashina
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-10 (2024)
Abstract Background Conventional, non-specific preventive migraine treatments often demonstrate low rates of treatment persistence due to poor efficacy or tolerability. Effective, well-tolerated preventive treatments are needed to reduce migraine sym
Externí odkaz:
https://doaj.org/article/04ca5a47ea8141e181232ded6eeb22d4
Autor:
Jessica Ailani, Peter McAllister, Paul K. Winner, George Chakhava, Mette Krog Josiassen, Annika Lindsten, Bjørn Sperling, Anders Ettrup, Roger Cady
Publikováno v:
BMC Neurology, Vol 23, Iss 1, Pp 1-3 (2023)
Externí odkaz:
https://doaj.org/article/74b9e03eabc54ec69c44e66f52f72882
Publikováno v:
Pain and Therapy, Vol 12, Iss 3, Pp 655-669 (2023)
Abstract Introduction Nonsteroidal anti-inflammatory drugs (NSAIDs) have been the first-line choice for the acute treatment of migraine attacks for decades; however, the safety of a particular NSAID is related to its treatment dose, duration, and mec
Externí odkaz:
https://doaj.org/article/f35a833535ce4d27a613ba164fde72eb
Autor:
Stewart J. Tepper, Jessica Ailani, Sutapa Ray, Joe Hirman, Stephen B. Shrewsbury, Sheena K. Aurora
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-13 (2022)
Abstract Background Headache recurrence is a common feature of acute therapies, whether approved or still in development, and continues to be a significant problem for both the patient and the clinician. Further complicating this issue is lack of sta
Externí odkaz:
https://doaj.org/article/2856343935984219ba57100a44c2299d
Autor:
Jessica Ailani, Peter McAllister, Paul K. Winner, George Chakhava, Mette Krog Josiassen, Annika Lindsten, Bjørn Sperling, Anders Ettrup, Roger Cady
Publikováno v:
BMC Neurology, Vol 22, Iss 1, Pp 1-8 (2022)
Abstract Background Eptinezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody approved for the preventive treatment of migraine. In the phase 3 RELIEF study, eptinezumab resulted in shorter time to headache pain freedom and ti
Externí odkaz:
https://doaj.org/article/e24f6974792545e39ab543c442df599f
Autor:
Peter McAllister, Paul K. Winner, Jessica Ailani, Dawn C. Buse, Richard B. Lipton, George Chakhava, Mette Krog Josiassen, Annika Lindsten, Lahar Mehta, Anders Ettrup, Roger Cady
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-10 (2022)
Abstract Background Demonstrating therapeutic value from the patient perspective is important in patient-centered migraine management. The objective of this study was to investigate the impact of eptinezumab, a preventive migraine treatment, on patie
Externí odkaz:
https://doaj.org/article/01048f33773d406b8c9421698d8a7692
Publikováno v:
Therapeutic Advances in Drug Safety, Vol 13 (2022)
Comprehensive methods for evaluating safety are needed to objectively assess the full risk profile of a medication. The confidence of the prescribing provider in the safety and effectiveness of pharmaceuticals is extremely important. Pharmacovigilanc
Externí odkaz:
https://doaj.org/article/429f0d404037493a842be32b7779322a
Publikováno v:
The Journal of Headache and Pain, Vol 21, Iss 1, Pp 1-9 (2020)
Abstract Background Focus on the frequency of migraine pain may undervalue the total burden of migraine as pain duration and severity may present unique, additive burden. A composite measure of total pain burden (TPB; frequency, severity, and duratio
Externí odkaz:
https://doaj.org/article/54ef347b35ed4aff8c8a0a3979dce2e0